Knee implant study halted early: what we know

NCT ID NCT00734110

Terminated Disease control Sponsor: DePuy International Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well the P.F.C. Sigma knee replacement implant works in people with severe knee arthritis. Researchers planned to follow 723 patients for at least 5 years after surgery, tracking pain, function, and any complications. However, the study was terminated early, so the full long-term data is not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P.F.C. Sigma Total Knee System (a knee replacement implant)
What this could lead to: If successful, this could confirm that the P.F.C. Sigma knee implant provides lasting pain relief and improved function for people with severe knee arthritis.
What could go wrong: The study was terminated early, so results may be incomplete. As a device study, individual outcomes vary and risks include implant failure, infection, or need for revision surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AVASCULAR NECROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avascular necrosis osteoarthritis, knee rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS

Contacts and locations

Locations

Princess Alexandra Hospital NHS Trust

Harlow, Essex, CM20 1QX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.